RxDoctor Payments Data

Lenka Rychetsky, MD

Internal Medicine · Tucson, AZNPI 1043286024

Payments from drug & device makers

$3,815in general payments, 2019–2025

Across 163 payments — averaging $23.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$682
  • Treace Medical Concepts, Inc.$450
  • Lilly USA, LLC$376
  • Novo Nordisk$357
  • AstraZeneca$270
  • GSK$233
  • plus $1K from 22 others

What the payments were for

  • Food & beverage$3,815100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,815 in reported general payments places this provider in the 90th percentile of 2,212 internal medicine providers in Arizona.

See all internal medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$80,338
Medicare patients
137
Services billed
2,141

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide97$131,036
JardianceEmpagliflozin80$88,281
XareltoRivaroxaban27$30,997
Repatha SureclickEvolocumab26$22,820
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$18,936
EliquisApixaban22$17,155
Breo ElliptaFluticasone/Vilanterol12$8,907
GemtesaVibegron11$8,792
Rosuvastatin Calcium441$5,775
SymbicortBudesonide/Formoterol Fumarate14$4,416
SynthroidLevothyroxine Sodium33$3,723
Duloxetine Hcl107$2,827
Ezetimibe82$2,553
Clonidine23$1,654
Estradiol15$1,375

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$376$131,03697 claims
Boehringer IngelheimJardiance$166$88,28180 claims
Johnson & JohnsonXarelto$28$30,99727 claims
GSKTrelegy Ellipta, Breo Ellipta$233$27,84332 claims
PfizerEliquis$100$17,15522 claims
AstraZenecaSymbicort$270$4,41614 claims
AbbVieSynthroid$115$3,72333 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,212 internal medicine providers in Arizona.

Other internal medicine in Tucson

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →